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Abstract 20 
The role of the Warburg effect in cancer remains to be elucidated with a resurgence in 21 
research efforts over the past decade. Why a cancer cell would prefer to use energy inefficient 22 
glycolysis, leading to an alteration of pH both inside and outside of the cell, remains to be 23 
uncovered. The development of MDR represents a major challenge in the treatment of cancer 24 
and it is explained, so far, by the over expression of drug transporters such as the well-known 25 
and archetypal P-glycoprotein (Pgp). However, controversies exist regarding the function of 26 
Pgp in multi-drug resistance. We suggest here that Pgp-mediated MDR relies fundamentally 27 
on pH alterations mediated by the Warburg effect. Furthermore, we propose that the use of 28 
proton pump and/or transporters inhibitors (PPIs/PTIs) in cancer are key to controlling both 29 
MDR, i.e. sensitize tumors to antineoplastic agents, and drug-related adverse effects.       30 
  31 
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A lost connection between research fields 32 
Over time, fields of scientific research gain autonomy in proportion to the extent to which 33 
they have been freed from economic necessity [1]. They develop their own laws and logics 34 
which become field-specific and very often run contrary to those in surrounding fields. They 35 
develop increasingly specialized research programmes and these can lead to great 36 
achievements. As the classical German social theorist Max Weber observed, ‘only by strict 37 
specialization can the scientific worker become fully conscious, for once and perhaps never 38 
again in his lifetime, that he has achieved something that will endure’ [2]. However, Weber 39 
also saw the melancholy aspect of ultra-specialization: it leads to the development of research 40 
fields that are incommensurable and between which communication is increasingly difficult. 41 
It also leads to scientists 'putting the blinkers on' in relation to developments outside their 42 
areas of expertise. For example, the somatic mutation theory of cancer together with the “war 43 
on cancer” have paved the way to great achievements in molecular biology (e.g. genome 44 
project) but their applications to medicine, i.e. oncology, remain minimal since the “magic 45 
bullet”, i.e. the one gene mutated – one drug concept, that was initially promised is still 46 
missing. The constant refining process that accompanies ultra-specialization in scientific 47 
fields is comparable to that which occurred in the field of abstract art where, through a 48 
process of purification that gradually isolated it from all reference to the wider social world, it 49 
became almost entirely propelled by its own inner dialectic [3]. We see here that in its 50 
‘purified’ state, a field becomes inward-looking.  51 
The results of specialization can be seen in the sub-field of research on MDR in cancer, 52 
which suffers from an inherent fundamental paradox. As early as 1973 the drug efflux 53 
hypothesis was suggested by Dano Keld [4], which was reinforced in 1976 when Juliano and 54 
Ling discovered Pgp in multi drug resistant cells [5]. Since then many works have been 55 
carried out to understand the function of Pgp in MDR. However the single use of Pgp to 56 
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explain MDR in cancer is flawed as Pgp violates the law of enzyme affinity/specificity on 57 
which the entire field of molecular biology is built: ‘MDR protein is a very unusual enzyme 58 
with extraordinarily broad substrate recognition capabilities; that is, it violates the law of 59 
enzyme specificity’ [6]. What is staggering is that even with the presence of a true scientific 60 
paradox in Pgp-mediated MDR in cancer, a range of stakeholders, whether economic and 61 
market-oriented (Big Pharma), institutional (academia, research organizations) or political 62 
(government, pressure groups), have shared (for most are still sharing) many of the same 63 
presuppositions about the problem of MDR in cancer and how it might be combatted, 64 
although rare attempts exist to suggest changes of strategy in the field of Pgp-mediated MDR 65 
[7].  66 
Why is this so? As scientists we know it, because specialist research fields tend to engender 67 
in scientists who have been trained in the field, and are thus attuned to its logic, an implicit 68 
sense of what is the correct way of doing science and this can inhibit them from gaining 69 
insights from other fields [8].  70 
No one would contest the existence of drug efflux mediated by membrane pumps. The 71 
question is simply that if membrane pumps exist in MDR cells, how can they work while, at 72 
the same time, violating the law of enzyme specificity? Is it really drug transporters that are 73 
important or have we overlooked essential components in multi drug resistant cancer cells?  74 
When faced with an apparent paradox it is essential to step out from the discipline and 75 
research around how similar issues are dealt with in other fields of enquiry. Understanding 76 
the importance of pharmacokinetic / drug delivery is essential to uncover how a drug may or 77 
may not cross the bilayer membrane of MDR cells. 78 
To explore the existing connections between MDR in cancer and other fields one will start by 79 
recalling concepts used in the field of pharmacokinetics that deals with similar barriers 80 
constituted by ATP-ase drug transporters. We shall see that in this context, the Big Pharma 81 
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industry have focused on determining the optimal biophysical properties of drugs to cross 82 
those barriers (irrespective of drug transporters). Next we shall investigate how those 83 
biophysical properties emerge by a clearer understanding of membrane physics. This will 84 
allow one to underline a number of studies that have emphasized the important role of the 85 
membrane in MDR in cancer. We shall then explain how the notion of specificity or affinity 86 
is not required as far as Pgp is involved. Finally, one will demonstrate how the Warburg 87 
effect and related changes in pH are involved in changing the membrane in such a way to 88 
sustain Pgp activity and MDR.  89 
In conclusion we will discuss about the role of proton pump inhibitors (PPIs) and membrane-90 
bound proton transport inhibitors (PTIs) to circumvent MDR and improve drug efficacy in 91 
cancer.  92 
  93 
The notion of pharmacokinetics and how it can help in understanding the MDR 94 
paradox 95 
The field of pharmacokinetics deals with how drug chemicals are dealt with by complex body 96 
systems and as a result how drug chemicals reach their targets. Defining the drug transporters 97 
that “cover” biological barriers has been essential for the success of the pharmaceutical 98 
industry. The main difference between the field of molecular oncology and pharmacokinetics 99 
is that the former works with simple systems (molecules and cells) whereas the later deals 100 
with complex body systems. Looking at how the Big Pharma has dealt with biological 101 
barriers may yield novel findings that could help to further define MDR.  102 
The’ 90s were gloomy years for the pharmaceutical industry with productivity falling below 103 
expectations and an average innovation deficit of ~1.3-1.8 for new chemical entities per year 104 
[9]. During this period these companies adopted approaches that relied on retrieval of 105 
information to determine if a chemical would make a ‘likely’ drug in advance of costly 106 
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clinical trials. To this end, Lipinski and collaborators [10] produced a set of rules that 107 
attempted to identify the best statistical physico-chemical properties required for an oral 108 
compound to achieve maximum bioavailability, i.e. to cross all biological barriers (where 109 
drug transporters are present) before reaching its target. The first of Lipinski’s rules is based 110 
on the lipophilic index of the drug, the second on the drug’s molecular weight (abbreviated 111 
“MW” in the remaining text) and the third and fourth rules concern the drug’s electrostatic 112 
charge properties. These rules are now established drug discovery paradigms and have been 113 
largely embraced by the pharmaceutical industry. Of the four rules, the second (MW<500) 114 
stands out by way of its apparent simplicity, being unrelated to complex physico-chemical 115 
properties of a drug (as is the charge or lipophilic index) but governed solely by a drug’s size 116 
or volume. This simplicity infers that basic mechanics apply when drugs cross membranes, 117 
cells, tissues and biological barriers. 118 
What is worth considering are the following points: (i) The Big Pharma did not focused on 119 
drug transporters and Linpinski’s rules do not mention drug transporter expression levels 120 
when barriers to drugs are considered and; (ii) the drug volume and thus some mechanical 121 
properties needs to be considered when drugs cross complex biological barriers. 122 
The next question is why and how biophysics is involved in drug efficacy?   123 
 124 
Why is the drug MW so important to cross barriers? An introduction to the biophysics 125 
of drug-membrane interactions. 126 
To be (bio)available, drugs must traverse cellular barriers – usually the epithelium or 127 
endothelium (e.g. of the gastrointestinal tract, renal tubules or the blood-brain and blood-128 
placenta barriers). To traverse cellular barriers, drugs must cross lipid membranes, and for 129 
this Lipinski’s 2nd rule postulates that drugs must have a MW<500. Therefore, in the sum of 130 
energies making up the total activation energy required for a drug to cross cellular 131 
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membranes a term must exist to underline the role of the membrane. In this case, i.e. when 132 
the plasma membrane is considered as a flat object, the physical parameter that best fits such 133 
an interaction is the membrane leaflets’ surface tension (  and unit mN /][  )1. Of course 134 
the surface tension parameter needs a proper definition especially in cells. All lipids are 135 
amphipathic molecules and as a result optimize their individual surface area in membrane 136 
leaflet. This optimization results from the energy balance between steric and/or electrostatic 137 
repulsion(s) (related to lipids’ head) and the lipid contact with water (related to the 138 
hydrophobic aliphatic chain(s)). This balance defines the surface tension. Now, when a drug 139 
enters a membrane leaflet it will have to “squeeze in” and compress the lipids of the leaflet, 140 
namely change the surface tension. This impact on the energy balance of lipids composing 141 
the leaflet will have a tendency to repulse, i.e. push out, the drug from the leaflet. However 142 
this process is not totally rigid as otherwise chemicals would never cross membranes. In fact, 143 
lipids are not static as the thermal agitation exists which allows for some flexibility. So if a 144 
small enough chemical incorporates into the leaflet and perturbs it in such a way that the 145 
resulting membrane energy is below the ambient thermal energy, then the lipids composing 146 
the leaflets will not “feel” any difference between the thermal agitation and the incorporation 147 
of the drug. So a drug can incorporate a membrane leaflet if it is small enough.    148 
Dimensionally speaking, it follows that a critical cross section for the drug ( ca ) can be 149 
defined simply by: /~ Tka Bc , where TkB  is the thermal energy ( Bk  is Boltzmann’s 150 
constant and T  the absolute temperature). If the cross section of a drug is lower than the 151 
                                           
1 Thermodynamically speaking, the physical parameters that are related to spatial dimensions 
(namely, volume (V), cross section area (a) or line (r)) are the pressure “P”: E=-P.V, the 
surface tension “”: E=.a, and the tension line “”: E=.r. “” is the differential 
operator and “E” the energy. As far as a membrane is considered, it is the surface tension 
(and thus the cross section area of the drug) that best describes the mechanical (i.e. physical) 
interaction and is deduced by posing E~kBT.  
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critical value it will incorporate and cross the membrane leaflet, but if it is higher the drug 152 
will be blocked.  153 
In bilayer membranes, two types of membrane surface tension can be distinguished, the mean 154 
surface tension noted 0 , which corresponds to the sum of the individual leaflet’s surface 155 
tension, and the difference in surface tensions  , which corresponds to the difference 156 
between individual leaflet’s surface tension. Using optical techniques, M. Sheetz and his 157 
collaborators have demonstrated that cells have a large reservoir of membrane [11] and an 158 
average membrane tension that is remarkably low ( mmN /003.0~0 ) [12]. On the other 159 
hand, the difference in surface tensions between leaflets has been demonstrated to be much 160 
higher mmN /9.0~  [13]. Accordingly, and given the magnitude of this parameter, it is 161 
more likely to be involved in impairing the transverse movement of chemicals. The previous 162 
equation can thus be refined as follows: /~ Tka Bc . Dealing with a parameter as   is 163 
not intuitive and the last equation needs to be resolved physiologically. A fundamental aspect 164 
of the difference in surface tension corresponds to its role in pinocytosis associated with the 165 
role of specific lipid flippases maintaining the membrane lipid asymmetry [14]. A direct 166 
consequence associated with this asymmetry is a more highly packed inner leaflet as it 167 
contains more phospholipids than the outer leaflet resulting in the difference in surface 168 
tensions ( mmNout /9.0~int  ) between the inner (cytosolic) and outer leaflets of 169 
the cell plasma membrane. Naturally, bilayer membranes are soft objects and as such, will 170 
attempt to release this stored energy. Accordingly, it has been demonstrated that lipid 171 
asymmetry corresponds to the physiological motor force that triggers membrane budding, 172 
leading to endocytosis (Figure 1) [13, 15, 16]. It is therefore possible to demonstrate that the 173 
vesicle radius is written as [13]:  hkR c /8 ; where ck  is the cell membrane bending 174 
modulus and h  the membrane thickness. As for drugs small enough that their MW is 175 
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proportional to their Van der Walls’ volume (expressed in 
3A ), i.e. 2/3~~ aVMW , a critical 176 
MW ( cMW ) can be determined given by:  177 
2/3)8/)(3/4( cBc kThRkMW         (Eq.1) 178 
The later relation provides a law with regard to the drugs size (or MW) selectivity on their 179 
permeation across cellular membranes: 250240cMW   at 37C [17]. As the MW cut off 180 
defined by Lipinski’s 2nd rule, i.e. 500cMW , describes the 90
th percentile; the former value 181 
(i.e. 250240cMW ) is an average in line with Lipinski’s rule. Two other important results 182 
follow. The first one is that it is also possible to demonstrate that the kinetics of membrane 183 
endocytosis is inversely proportional to the vesicle radius [18], i.e.: 184 
Rkendo /1~           (Eq.2)    185 
And that the kinetics of transverse movement across the membrane is [17]: 186 








 EndoDrug kMWAk
3
2
exp~        (Eq.3) 187 
Where, A, is a constant. It does seem that Lipinski’s 2nd rule can be explained by considering 188 
simple biophysical arguments and that the membrane plays a key role in this process. But 189 
what about drug resistant cancer cells?    190 
 191 
Are alterations in the cell membrane observed in MDR and is the drug MW important 192 
in multi drug resistant cells? 193 
From what was seen above, if the drug MW is important it is because the membrane is also 194 
involved. So changes in the lipid membrane composition and membrane recycling should be 195 
expected in drug resistant cells and this seems to clearly be the case. Different studies have 196 
reported changes in membrane composition including neutral lipids, phospholipids, 197 
cholesterol and fatty acids [19-24], in some cases related to a change in the lipid metabolism 198 
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of drug resistant cells [22, 25, 26]. This point has been particularly well underlined when the 199 
lipid profile of released exosomes was analysed [27]. Also, ultrastructure studies have 200 
revealed an increased density of small and large membrane organelles [22, 28-32] and an 201 
increase in the kinetics of membrane endocytosis or membrane recycling [29-31, 33, 34] in 202 
drug resistant cells. It is noteworthy that the release of exosomes is also involved in MDR 203 
[35].What is perhaps more important is that the MW of a drug itself was also underlined very 204 
early (in 1970) in MDR studies in line with the role that the membrane has in delaying a 205 
chemicals influx [36, 37]. It is worth noting here that the role of a drugs MW was underlined 206 
prior to the discovery of Pgp by Juliano and Ling in 1976  [5]. The connection between 207 
membrane endocytosis and the size of a drug chemical with passive influx/uptake of drugs 208 
into cells is given by the set of equations described above.  209 
The data points clearly to the membrane as a strong effector of drug resistance but why would 210 
the membrane be so central when drug transporting is involved in MDR?   211 
 212 
Drug-membrane biophysical interactions to resolve the multi specificity of drug 213 
transporters 214 
It is very often suggested that drug transporters work similarly to enzymes in line with the 215 
notion of affinity, namely that a drug needs to interact with a transporter to activate the 216 
transporter and be expelled. However this view does not work for at least three reasons when 217 
focusing on Pgp: (i) the ATP concentration in cells is usually 3-5mM that always exceeds the 218 
affinity of Pgp for ATP (KmATP~0.3-1mM) [38, 39], suggesting that the transporter is always 219 
“active”. (ii)  Pgp ATPase activity is relatively independent of the presence of drugs [40], and 220 
the affinity of drugs toward transporters is chiefly dependent on their affinity toward the 221 
membrane [41]. Finally (iii), the apparent stoichiometry of the hypothesized ATP-coupled 222 
active drug transport, i.e. the number of ATP molecules hydrolyzed per drug transported, can 223 
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be enormous (calculated to be up to ~36000ATP/drug in reconstituted proteo-liposomes) [6, 224 
38]. This suggests that while consuming ATP Pgp does not necessarily lead to drug extrusion.  225 
Due to the fact that similar conclusions cannot be drawn for drug transporters other than Pgp 226 
due to lack of experimental observations, Pgp remains the archetypal transporter involved in 227 
MDR and it is believed that Pgp is very likely continuously recycling between “open” and 228 
“closed” states by over-consuming ATP. This may explain why Pgp and drug resistance are 229 
so sensitive to cellular metabolism [42]. It is interesting to note that Pgp activity leads to a 230 
parallel acidification of the extracellular medium [43] that, in turn, is thought to be related to 231 
initial metastatic steps [44]. Given that the vast majority of metastatic tumours are also multi 232 
drug resistant [45], the recycling between open and closed conformations is likely to be 233 
essential to explain the multi of drug resistance [46]. 234 
Here comes an essential point. If Pgp switches between open and closed conformations 235 
independently of drugs, what is essential in MDR is that for drugs to be expelled they must 236 
remain in the membrane long enough to encounter (or collide with) Pgp. From Eq.3 the 237 
kinetics of drug transverse movement is modulated exponentially by two physical parameters 238 
related to the biophysical state of the membrane involving the size of the drug (see above) 239 
and the kinetics of endocytosis (see below). An increase in the kinetics of membrane 240 
endocytosis supporting Pgp function is possible if the Warburg effect and relatively high 241 
cytosolic pH are considered.     242 
 243 
Cytosolic pH, endocytosis and MDR  244 
Regardless of their origin and genetic background cancer cells and tissues have been found to 245 
display an abnormality called “proton reversal” which describes the state by which a cell 246 
consists of an interstitial acidic microenvironment secondary to an initial, specific and 247 
etiopathogenic intracellular alkalosis [47-53]. A failure to induce intracellular acidification 248 
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and reverse this phenomenon in cancer tissues has been proposed to be the main factor 249 
underlying drug resistance including resistance to the induction of therapeutic apoptosis [54-250 
58]. Also, because inner leaflet lipids bear protonable polar heads, pH changes will modify 251 
their net charge. In turn this will impact on the sum of electrostatic repulsions and modify 252 
membrane difference in surface tension (i.e. decrease the size of pinocytic vesicles and as a 253 
result increase the kinetics of endocytosis) [59].  254 
To consider any effect of the cytosolic pH on lipid packing it is central to understand the 255 
notion of packing from a physics standpoint. At a constant membrane surface area, the lipid 256 
packing is given by the optimal area per lipid in the cell membrane. The latter is deduced 257 
from the balance between repulsions that occur mostly through electrostatic effects on the 258 
polar heads, and attractions, which concern more the hydrophobic and geometric effects that 259 
take place between the aliphatic chain(s). Any changes in this balance are expected to affect 260 
the optimal area per lipid (i.e. their packing) and membrane shape. As a non-negligible 261 
fraction of the inner leaflet consists of negatively charged lipids, such as phosphatidylserine 262 
or PIP2, for example [60] a slight increase in proton concentration around neutrality (e.g. 263 
decrease in cytosolic pH) will eliminate or shield these negative charges and decrease the 264 
electrostatic repulsion between polar groups. Although such an electrostatic counterion effect 265 
might in principle be generalized to intracellular cations, it is obvious that exchangeable 266 
protons will have a more pronounced effect on negatively charged lipids. As a final result, a 267 
low cytosolic pH is more likely to be central in abolishing the physical repulsion between 268 
lipids, and thus decreases the surface tension (i.e. the lipid packing of the cytosolic leaflet - 269 
note that both lipid packing and surface tension are proportional to each other). Such a 270 
relationship between free electrolytes and the cross section area per lipid in model 271 
biomembranes is well known experimentally [61-63]. A similar result was also obtained on 272 
living cells [64]. Conversely, when the cytosolic pH increases (i.e. when cells become reliant 273 
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on the Warburg effect), fewer positive charges will be available to mask the lipids charge, 274 
which in turn is expected to increase their repulsions and thus their packing. Thus, this higher 275 
lipid packing would increase the surface tension of the leaflet in contact with the milieu of 276 
elevated cellular pH in the case of drug resistant cells. So, if the pH affects the packing of 277 
lipids, and the packing of lipids affects the intracellular accumulation of drugs, it follows that 278 
the cytosolic pH should affect the intracellular accumulation of those drugs. As a result, the 279 
changes in cytosolic pH observed when cells switch their state of resistance is an important 280 
clue for understanding the observed alterations of intracellular accumulation of drugs as a 281 
function of their size. This way of thinking has permitted the theoretical corroboration of the 282 
connection between the cytosolic pH (linked to Warburg effect), the membrane biophysical 283 
properties and the MDR levels in several cell types [59] (see figure 2). The interaction 284 
between the membrane and the cytosolic pH can explain why PPIs overcome the Pgp-285 
mediated MDR [65].  286 
 287 
Beyond the cell membrane  288 
Using arguments and results developed by us and others the general view is that drug 289 
sensitivity or drug resistance can only be understood if one steps outside of a Pgp-centred 290 
view to engage with a holistic approach of cancer. This true and fundamental scientific 291 
approach is equivalent of saying that what has been exposed in this review needs to be duly 292 
criticized as well to push the boundary that it creates under the form of a new research field. 293 
In the context of drug sensitivity (or drug resistance or drug refractoriness) in cancer it is 294 
essential to underline the fact that many interactions between the various cellular 295 
compartments exist that underlines the complexity of the disease that, in turn, may provide 296 
fundamental clues as to how MDR progresses. An illuminating study performed in resinless 297 
ultrathin EM sections has shown that a staggering network of interconnected cytoskeletal 298 
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filaments does exist between polyribosomes, mitochondria and a myriad of unidentified small 299 
structures attached to the cytoskeleton [66]. Using the same technique, the nuclear space 300 
appears as a complex network of core filaments connecting with the nuclear lamina, and the 301 
chromosomes appear attached to spindle fibers, which are in turn interconnected through 302 
several thin filaments. None of these structures are visible using conventional resin 303 
embedding technique. This introduces the concept that the cell has to be considered as a 304 
whole, and that this whole is not entirely known also because of the compartmentalization of 305 
the research approaches; and this is true for MDR as well. In general the membrane to 306 
cytoskeleton connection is entirely deranged in cancer cells, determining an aberrant cell 307 
polarization in turn related to the metastatic behaviour [67]. Research has been carried out 308 
showing that Pgp is linked to actin through ERM and that this connection is key for MDR in 309 
human tumor cells [68, 69]. How such interaction can be understood in the framework 310 
provided by the membrane is unclear but it underlines that fact that cells should be 311 
considered in a holistic way, also because cancer cells are independent and behave as an 312 
unicellular microorganism committed to survive in a very hostile environment [70]. 313 
 314 
Conclusion: From bench to bedside  315 
While MDR remains linked to drug transporters, alterations in pH gradient resulting from the 316 
Warburg effect across the cell membrane or organelles is well known to impact on the 317 
biophysical properties of the cancer cell membrane sustaining drug transporter activity. 318 
Therefore it is in theory possible to improve drug uptake by cells by normalizing the pH 319 
using PPIs. This point was demonstrated recently in tumor sarcospheres [71]. Furthermore 320 
the same study demonstrated that tumor sarcospheres were becoming more sensitive to lower 321 
drug doses of anticancer agents raising hope that adverse effects linked to the administration 322 
of chemotherapy could, one day, be reduced or controlled in patients [71].  PPIs are amongst 323 
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the most commonly prescribed drugs in human medicine and have gone through the process 324 
of rigorous safety testing and monitoring. Very few clinical side effects are seen even at 325 
higher doses and as such it seems easy to justify the continued investigation into the use of 326 
this class of drug for the treatment of cancer in companion animals [71-74] and humans [75-327 
78]. They may provide an alternative or additional source of therapy to animals and humans 328 
which could result in lower treatment costs, greater availability and safer handling compared 329 
to current cytotoxic protocols. PPIs and PTIs could potentially form part of a universal 330 
treatment which may have direct benefits in treating a number of different cancer types while 331 
combating problems associated with chemotherapy such as drug resistance, severe side-332 
effects and even death secondary to present day chemotherapy. 333 
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Legends 565 
 566 
Figure 1: (A) Lipid asymmetry at the vesicular scale: Given the small size of vesicles, the 567 
radius and membrane thickness are relatively close together ( 10~/ hR ). Thus, the outer 568 
leaflet of a vesicle ( outS ) has significantly more lipids than the inner leaflet ( inS ). As the 569 
vesicle is spherical, noting 2
0 4 RS   the neutral surface area namely the surface area 570 
between the outer and inner leaflets, it follows at the first order that 571 
)/1(~)2/(4 0
2 RhShRSout    and )/1(~)2/(4 0
2 RhShRSin   . Thus 572 
RhSSS inout /~ 0  . (B) Sketch representing the current model linking fluid phase 573 
endocytosis to the membrane phospholipid number asymmetry [14]. In the left panel, the 574 
translocation of dark-headed lipids into the inner leaflet induces a differential packing of 575 
lipids between leaflets leading to membrane bending and vesiculation [13, 15]. Note the 576 
membrane recycling that occurs in cells (right panel), i.e. the exocytosis of vesicles with a 577 
size similar to endocytic vesicles, allows the maintenance of lipid asymmetry and thus the 578 
maintenance of the differential packing of leaflets at the level of the plasmalemma. 579 
Accordingly, the lipid number asymmetry has been experimentally deduced from studies on 580 
drug sensitive cells (K562)  with a value %4/ 0  NN  providing a ~35nm vesicle radius 581 
[13]. (C) Representation of the different energy barriers (noted together )(xU ) and involved 582 
when a drug traverses the bilayer cellular membrane. Two leaflets have been represented with 583 
an inner leaflet containing more phospholipids related to the increase in the difference in 584 
surface tensions (upper graph). Energy profiles of lipid packing in both leaflet (plain curve-585 
middle graph) and hydrophobic core of membrane (dashed curve-middle graph) are both 586 
involved in providing penalty energies with regard to the transbilayer movement of drugs. As 587 
the inner leaflet is packed, drugs crossing the membrane will be trapped in this leaflet which 588 
22 
 
will delay and impair their flow into the cytosol [79]. The latter effect will be dependent on 589 
the size of drugs as bigger drugs will “feel more strongly” this mechanical barrier. In the 590 
present paper, this effect is supposed to be central for the high levels of cross resistance to 591 
drugs.  592 
 593 
Figure 2: (A) Comparison between experimentally measured doxorubicin resistance levels 594 
obtained in cells (blanked circles) and the theory (filled circles). The open circles 595 
corresponding to SW1573 (lung derived cancer cells), K562R (leukemic cancer cells) and 596 
MCF-7R (breast derived cancer cells) are indicated with arrows and labels. Finally the 597 
straight line is the linear regression of experimental data which agrees very well with the 598 
theory.   599 
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